Literature DB >> 25628920

Prognostic significance of minichromosome maintenance proteins in breast cancer.

Hang Fai Kwok1, Shu-Dong Zhang2, Cian M McCrudden2, Hiu-Fung Yuen3, Kam-Po Ting4, Qing Wen2, Ui-Soon Khoo4, Kelvin Yuen-Kwong Chan4.   

Abstract

A role for the minichromosome maintenance (MCM) proteins in cancer initiation and progression is slowly emerging. Functioning as a complex to ensure a single chromosomal replication per cell cycle, the six family members have been implicated in several neoplastic disease states, including breast cancer. Our study aim to investigate the prognostic significance of these proteins in breast cancer. We studied the expression of MCMs in various datasets and the associations of the expression with clinicopathological parameters. When considered alone, high level MCM4 overexpression was only weakly associated with shorter survival in the combined breast cancer patient cohort (n = 1441, Hazard Ratio = 1.31; 95% Confidence Interval = 1.11-1.55; p = 0.001). On the other hand, when we studied all six components of the MCM complex, we found that overexpression of all MCMs was strongly associated with shorter survival in the same cohort (n = 1441, Hazard Ratio = 1.75; 95% Confidence Interval = 1.31-2.34; p < 0.001), suggesting these MCM proteins may cooperate to promote breast cancer progression. Indeed, their expressions were significantly correlated with each other in these cohorts. In addition, we found that increasing number of overexpressed MCMs was associated with negative ER status as well as treatment response. Together, our findings are reproducible in seven independent breast cancer cohorts, with 1441 patients, and suggest that MCM profiling could potentially be used to predict response to treatment and prognosis in breast cancer patients.

Entities:  

Keywords:  Minichromosome maintenance complex; breast cancer; prognosis; survival

Year:  2014        PMID: 25628920      PMCID: PMC4300722     

Source DB:  PubMed          Journal:  Am J Cancer Res        ISSN: 2156-6976            Impact factor:   6.166


  47 in total

Review 1.  MCM proteins in DNA replication.

Authors:  B K Tye
Journal:  Annu Rev Biochem       Date:  1999       Impact factor: 23.643

2.  Strong time dependence of the 76-gene prognostic signature for node-negative breast cancer patients in the TRANSBIG multicenter independent validation series.

Authors:  Christine Desmedt; Fanny Piette; Sherene Loi; Yixin Wang; Françoise Lallemand; Benjamin Haibe-Kains; Giuseppe Viale; Mauro Delorenzi; Yi Zhang; Mahasti Saghatchian d'Assignies; Jonas Bergh; Rosette Lidereau; Paul Ellis; Adrian L Harris; Jan G M Klijn; John A Foekens; Fatima Cardoso; Martine J Piccart; Marc Buyse; Christos Sotiriou
Journal:  Clin Cancer Res       Date:  2007-06-01       Impact factor: 12.531

3.  TP53 genomics predict higher clinical and pathologic tumor response in operable early-stage breast cancer treated with docetaxel-capecitabine ± trastuzumab.

Authors:  Stefan Glück; Jeffrey S Ross; Melanie Royce; Edward F McKenna; Charles M Perou; Eli Avisar; Lin Wu
Journal:  Breast Cancer Res Treat       Date:  2011-03-04       Impact factor: 4.872

4.  Cancer-associated expression of minichromosome maintenance 3 gene in several human cancers and its involvement in tumorigenesis.

Authors:  Seon-Ah Ha; Seung Min Shin; Hong Namkoong; Heejeong Lee; Goang Won Cho; Soo Young Hur; Tae Eung Kim; Jin Woo Kim
Journal:  Clin Cancer Res       Date:  2004-12-15       Impact factor: 12.531

5.  mRNA expression of minichromosome maintenance 2 in colonic adenoma and adenocarcinoma.

Authors:  Yong Wang; Yuan Li; Wen-Yan Zhang; Qing-Jie Xia; Hong-Guang Li; Rong Wang; Lie Yang; Xiao-Feng Sun; Zong-Guang Zhou
Journal:  Eur J Cancer Prev       Date:  2009-02       Impact factor: 2.497

6.  Diagnosis of genito-urinary tract cancer by detection of minichromosome maintenance 5 protein in urine sediments.

Authors:  Kai Stoeber; Robert Swinn; A Toby Prevost; Pamela de Clive-Lowe; Ian Halsall; Stephen M Dilworth; Jackie Marr; William H Turner; Nigel Bullock; Andrew Doble; C Nicholas Hales; Gareth H Williams
Journal:  J Natl Cancer Inst       Date:  2002-07-17       Impact factor: 13.506

Review 7.  MCM proteins as diagnostic and prognostic tumor markers in the clinical setting.

Authors:  Constantinos Giaginis; Stephanie Vgenopoulou; Philippe Vielh; Stamatios Theocharis
Journal:  Histol Histopathol       Date:  2010-03       Impact factor: 2.303

8.  Gene expression profiling spares early breast cancer patients from adjuvant therapy: derived and validated in two population-based cohorts.

Authors:  Yudi Pawitan; Judith Bjöhle; Lukas Amler; Anna-Lena Borg; Suzanne Egyhazi; Per Hall; Xia Han; Lars Holmberg; Fei Huang; Sigrid Klaar; Edison T Liu; Lance Miller; Hans Nordgren; Alexander Ploner; Kerstin Sandelin; Peter M Shaw; Johanna Smeds; Lambert Skoog; Sara Wedrén; Jonas Bergh
Journal:  Breast Cancer Res       Date:  2005-10-03       Impact factor: 6.466

9.  Cell line derived multi-gene predictor of pathologic response to neoadjuvant chemotherapy in breast cancer: a validation study on US Oncology 02-103 clinical trial.

Authors:  Kui Shen; Yuan Qi; Nan Song; Chunqiao Tian; Shara D Rice; Michael J Gabrin; Stacey L Brower; William Fraser Symmans; Joyce A O'Shaughnessy; Frankie A Holmes; Lina Asmar; Lajos Pusztai
Journal:  BMC Med Genomics       Date:  2012-11-16       Impact factor: 3.063

10.  Mcm2 predicts recurrence hazard in stage Ta/T1 bladder cancer more accurately than CK20, Ki67 and histological grade.

Authors:  M Burger; S Denzinger; A Hartmann; W-F Wieland; R Stoehr; E C Obermann
Journal:  Br J Cancer       Date:  2007-05-15       Impact factor: 7.640

View more
  45 in total

1.  MCM2: An alternative to Ki-67 for measuring breast cancer cell proliferation.

Authors:  Einas M Yousef; Daniela Furrer; David L Laperriere; Muhammad R Tahir; Sylvie Mader; Caroline Diorio; Louis A Gaboury
Journal:  Mod Pathol       Date:  2017-01-13       Impact factor: 7.842

2.  Gain-of-Function Mutant p53 R273H Interacts with Replicating DNA and PARP1 in Breast Cancer.

Authors:  Gu Xiao; Devon Lundine; George K Annor; Jorge Canar; Viola Ellison; Alla Polotskaia; Patrick L Donabedian; Thomas Reiner; Galina F Khramtsova; Olufunmilayo I Olopade; Alexander Mazo; Jill Bargonetti
Journal:  Cancer Res       Date:  2019-11-27       Impact factor: 12.701

3.  Discovery of Tamoxifen and N-Desmethyl Tamoxifen Protein Targets in MCF-7 Cells Using Large-Scale Protein Folding and Stability Measurements.

Authors:  Ryenne N Ogburn; Lorrain Jin; He Meng; Michael C Fitzgerald
Journal:  J Proteome Res       Date:  2017-10-11       Impact factor: 4.466

4.  Identification of Key Components in Colon Adenocarcinoma Using Transcriptome to Interactome Multilayer Framework.

Authors:  Ehsan Pournoor; Zaynab Mousavian; Abbas Nowzari Dalini; Ali Masoudi-Nejad
Journal:  Sci Rep       Date:  2020-03-19       Impact factor: 4.379

5.  Regulation of HMGB3 by antitumor miR-205-5p inhibits cancer cell aggressiveness and is involved in prostate cancer pathogenesis.

Authors:  Yasutaka Yamada; Rika Nishikawa; Mayuko Kato; Atsushi Okato; Takayuki Arai; Satoko Kojima; Kazuto Yamazaki; Yukio Naya; Tomohiko Ichikawa; Naohiko Seki
Journal:  J Hum Genet       Date:  2017-12-01       Impact factor: 3.172

6.  Prognostic role of minichromosome maintenance family in multiple myeloma.

Authors:  Liang Quan; Tingting Qian; Longzhen Cui; Yan Liu; Lin Fu; Chaozeng Si
Journal:  Cancer Gene Ther       Date:  2020-01-21       Impact factor: 5.987

7.  Celastrol Modulates Multiple Signaling Pathways to Inhibit Proliferation of Pancreatic Cancer via DDIT3 and ATF3 Up-Regulation and RRM2 and MCM4 Down-Regulation.

Authors:  Mahmoud Youns; Momen Askoura; Hisham A Abbas; Gouda H Attia; Ahdab N Khayyat; Reham M Goda; Ahmad J Almalki; El-Sayed Khafagy; Wael A H Hegazy
Journal:  Onco Targets Ther       Date:  2021-06-23       Impact factor: 4.147

8.  LncRNA CARMN overexpression promotes prognosis and chemosensitivity of triple negative breast cancer via acting as miR143-3p host gene and inhibiting DNA replication.

Authors:  Xiaonan Sheng; Huijuan Dai; Yueyao Du; Jing Peng; Rui Sha; Fan Yang; Liheng Zhou; Yanping Lin; Shuguang Xu; Yifan Wu; Wenjin Yin; Jinsong Lu
Journal:  J Exp Clin Cancer Res       Date:  2021-06-23

9.  MCM6 indicates adverse tumor features and poor outcomes and promotes G1/S cell cycle progression in neuroblastoma.

Authors:  Yaoyao Gu; Xiaoxiao Hu; Xiaowei Liu; Cheng Cheng; Kai Chen; Yeming Wu; Zhixiang Wu
Journal:  BMC Cancer       Date:  2021-07-07       Impact factor: 4.430

10.  Aberrant MCM10 SUMOylation induces genomic instability mediated by a genetic variant associated with survival of esophageal squamous cell carcinoma.

Authors:  Jianbo Tian; Zequn Lu; Siyuan Niu; Shanshan Zhang; Pingting Ying; Lu Wang; Ming Zhang; Yimin Cai; Tianyi Dong; Ying Zhu; Rong Zhong; Zhihua Wang; Jiang Chang; Xiaoping Miao
Journal:  Clin Transl Med       Date:  2021-06
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.